Sphingolipid Drugs Triggering Nutrient Transporter Down-Regulation
These compounds may be developed for cancer therapies employing a novel mechanism of starving malignant cells. Specifically, these compounds could be useful for the treatment of certain blood-borne cancers and leukemias.
UCI researchers have designed and synthesized novel compounds that do not necessarily involve Fingolimod's S1P receptor-related, dose limiting toxicities. Specifically, the UCI researchers have designed a family of Azacyclic constrained analogs that overcome the dose-limiting toxicities of Fingolimod and down-regulate cellular nutrient transport. Studies in a mouse model suggest that these compounds do not exhibit undesirable cardio-vascular effects or sequester lymphocytes like Fingolimod.
2016015973
Tech ID/UC Case 23535/2013-802-0 Related Cases 2013-802-0, 2016-031-0
美国
